Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Aug 6, 2016; 7(3): 370-386
Published online Aug 6, 2016. doi: 10.4292/wjgpt.v7.i3.370
Published online Aug 6, 2016. doi: 10.4292/wjgpt.v7.i3.370
Toxic metabolic |
Xenobiotics |
Alcohol |
Cigarette smoking[12] |
Genetic mutations |
CFTR mutation (Cystic Fibrosis Transmembrane Conductance Regulator) PRSS1 mutation (Protease, Serine 1) |
SPINK1 mutation (Serine Peptidase Inhibitor, Kazal type 1) |
CTRC (chymotrypsin C) |
Chronic Obstruction of main pancreatic duct |
Cancer |
Post-duct destruction in severe attack |
Recurrent acute pancreatitis |
Autoimmune |
Idiopathic |
Early or late onset |
Tropical |
Episodic mild to moderate pain |
Constant mild to moderate pain |
Typically pain free between episodes of severe pain |
Constant mild pain with episodes of severe pain |
Constant pain |
Increased intraductal pressure |
Ductal obstruction from strictures/stones |
Increased intrapancreatic pressure (compartment-like syndrome) |
Fibrosis causing lack of distensibility |
Neuropathic |
Entrapment of nerves |
Damage of nerves by enzymes |
Increased nerve tissue |
Pancreatic ischemia |
Worsened during increased enzyme secretion |
- Citation: Hobbs PM, Johnson WG, Graham DY. Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes. World J Gastrointest Pharmacol Ther 2016; 7(3): 370-386
- URL: https://www.wjgnet.com/2150-5349/full/v7/i3/370.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i3.370